Education
About Us
Working with TipRanks
Follow Us
Scpharmaceuticals (SCPH)
:SCPH
Earnings Data
Report Date
May 20, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.3Last Year’s EPS
-0.36Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 19, 2025
|% Change Since: 0.00%
|Next Earnings Date:May 20, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment overall, with strong revenue growth and strategic advancements like the FDA approval for CKD. However, increased operating expenses and a higher net loss pose challenges. The company is optimistic about future growth driven by Medicare redesign and product expansion.Company Guidance
During the scPharmaceuticals Fourth Quarter and Full Year 2024 Earnings Conference Call, the company reported a net revenue of $12.2 million for Q4 2024, leading to a total of $36.3 million in net FUROSCIX revenue for the year, marking a 167% increase year-over-year. The company highlighted a gross-to-net (GTN) discount of approximately 19% for Q4 2024 and projected a long-term GTN discount range of 30% to 35% for 2025 due to the Medicare redesign. scPharmaceuticals announced the FDA's approval of a supplemental new drug application for FUROSCIX to treat edema in chronic kidney disease (CKD) patients, with a full launch expected in April 2025. The company also noted a significant increase in the number of doses prescribed, citing 13,300 doses filled in Q4 2024, up from 10,800 in Q3 2024. Additionally, the company ended 2024 with $75.7 million in cash and reported a Q4 net loss of $18.8 million. Looking ahead, scPharmaceuticals anticipates the Medicare redesign to positively impact FUROSCIX's market penetration and organic growth.Significant Revenue Growth
scPharmaceuticals reported $36.3 million in FUROSCIX net revenue for 2024, marking a 167% increase year-over-year.
FDA Approval for Expanded Use
The FDA approved FUROSCIX for the treatment of edema in patients with chronic kidney disease, expanding its market potential.
Increased Provider Adoption
Over 3,800 unique providers have prescribed FUROSCIX, with doses filled increasing by 23% in Q4 compared to Q3.
Positive Patient Co-pay Developments
The Medicare redesign is expected to lower patient out-of-pocket costs significantly, potentially increasing fill rates and demand.
Autoinjector Progress
Encouraging data from shelf-life testing of the Autoinjector, with a mid-year submission of the sNDA planned.
---
SCPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SCPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 19, 2025 | $3.04 | $3.01 | -0.99% |
| Nov 13, 2024 | $3.91 | $3.36 | -14.07% |
| Aug 14, 2024 | $4.79 | $5.06 | +5.64% |
| May 14, 2024 | $4.50 | $4.57 | +1.56% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Scpharmaceuticals (SCPH) report earnings?
Scpharmaceuticals (SCPH) is schdueled to report earning on May 20, 2025, TBA Not Confirmed.
What is Scpharmaceuticals (SCPH) earnings time?
Scpharmaceuticals (SCPH) earnings time is at May 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SCPH EPS forecast?
SCPH EPS forecast for the fiscal quarter 2025 (Q1) is -0.3.
---
